LATEST PRESS RELEASES

Global Comedy Star Russell Peters to Have a Psychedelic Journey with Red Light Holland’s Natural Psilocybin Truffles and Red Light Holland’s Therapist in Amsterdam

● Red Light Holland to live stream an intimate Russell Peters performance in front of a live audience, after he completes his journey, on multiple social media accounts● Red Light Holland to document Russell Peters moments in The Netherlands, as he will be accompanied by a camera crewToronto, Ontario--(Newsfile Corp. - October 15, 2021) -... Read More...

Ketamine Wellness Centers Partners with Veterans Affairs (VA) Community Care Network to Provide Free Ketamine Treatments to Veterans

Nation's Largest Clinic Chain's Partnership with Illinois and Minnesota Chapters to Provide Ketamine Treatments for PTSD, Depression and Pain at No Out-of-Pocket Cost VANCOUVER, BC, Oct. 14, 2021 - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source) the leading psychedelic wellness platf... Read More...

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

TORONTO, Oct. 13, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common shares have been approved for trading on the OTCQB® Venture Market (... Read More...

Red Light Holland Expands the iMicrodose Brand and Unveils New iMicrodose Products: Triniti, Uniti and Mindfuli

Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have unveiled new iMicrodose Products powered by Red Light... Read More...

Novamind Launches New Psychedelic Palliative Care Program

Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illnessTORONTO, ON / ACCESSWIRE / October 7, 2021 /Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic P... Read More...

Blackhawk Growth’s MindBio Therapeutics Brings Digital Mental Health Technology To Psychedelics Clinical Trials

Calgary, Alberta --News Direct-- Blackhawk Growth Corp.Vancouver, British Columbia - TheNewswire – October 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic ... Read More...

Allied Corp Announces Signing of Supply Contracts of 85,000, 40,000 and 24,000 Kilograms for the 2022 Calendar Year

KELOWNA, British Columbia, Oct. 07, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of supply contracts for the 2022 calendar. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (fo... Read More...

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Englewood Cliffs NJ, Oct. 07, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with ... Read More...

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment ExperienceVancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Krysalis VX Innovations Inc. ("Krysalis")... Read More...

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

TORONTO, Oct. 06, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient sc... Read More...

Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference

VANCOUVER, British Columbia, Oct. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright ... Read More...

Delic Labs Applies for Dealer’s License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

License Allows Authority to Work with Additional Banned Substances and Market the Research for Medical Purposes VANCOUVER, BC, Oct. 6, 2021 - Delic Holding Corp Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), the leading psychedelic wellness platform, today announced Delic Labs has applied for a He... Read More...

Red Light Holland Expands Product Offerings and Rebrands Maka Truffles as a Responsible Use Psychedelic

Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have expanded their product offerings with Maka magic truf... Read More...

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

DENVER, Oct. 05, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being con... Read More...

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications FirmTORONTO, October 01, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Ami... Read More...

Allied Corp Announces Approval of Research and Plant Breeding License for Psychoactive and Non-Psychoactive Cannabis in Colombia

KELOWNA, British Columbia, Sept. 30, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that is has been granted additional licensing that enables the Company to function as a research and plant breeding unit for psychoactive and non-psychoactive Cannabis in Colombia. The activities that are included in ... Read More...

Delic Partnership with Paradigm Healthcare of Georgia Brings Clinically Relevant Toxicology Testing to Ketamine Treatment for First Time

Psychedelic Treatment Chain Ketamine Infusion Centers Will Leverage State-of-the-Art Toxicology Testing Solution to Ensure Highest Quality Results Across Locations VANCOUVER, BC, Sept. 30, 2021 - Delic Holding Corp Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness pl... Read More...

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

TORONTO, Sept. 29, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor. Dr. Laughren will advise on regulatory matters as it pertains to KETABET™, ... Read More...

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint /NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, Sept. 29, 2021 - Delic Holdings Corp. ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously anno... Read More...

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

TORONTO, Sept. 28, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to announce that it has closed its previously announced private placement with institutional investors of its common shares (“Common Shares”) and warrants to purchase comm... Read More...

Pure Extracts and Psyence Group Form Joint Venture for Psychedelic Medicinal Mushroom Extracts

VANCOUVER, British Columbia, Sept. 28, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”) and Psyence Group Inc. (CSE: PSYG) (“Psyence”) are pleased to announce the incorporation of a joint venture company, Pure Psyence Corp. (“Pure Psyence” or the “JV”), for the development... Read More...

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD VANCOUVER, BC, Sept. 28, 2021 - Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical rese... Read More...

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Ex... Read More...

Lamar Odom and His Life-Saving Journey with Psychedelics

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwo... Read More...

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

First-of-its-kind study targets a female sexual disorder affecting an estimated 9.5 million women in the U.S. alone VANCOUVER, BC, Sept. 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, introduces its "Desire Project," a clinical ... Read More...

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

TORONTO, Sept. 24, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in ... Read More...

Novamind Announces DTC Eligibility for its Common Shares

TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the U.S.The DT... Read More...

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has entered into a securities purchase agreement with institutional investors... Read More...

Allied Corp Provides Results of Recent Third Party Audit Confirming Production Costs and Optimization of Production

KELOWNA, British Columbia, Sept. 24, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the results of a third party audit that was conducted at the Allied Colombian Campus. The focus of the audit was Allied’s cost of production, inventory control and optimization of its production approach. On September... Read More...

Microdose Psychedelic Insights Announces Entheon Biomedical, Levitee Labs, and Women in Psychedelics to take centre stage at Psychedelic Capital: September 30, 2021

Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: September 2021 conference to be taking place on September 30, 2021, starting at 1:30pm EDT. The September edition will engage in discussions on Novel Psychedelic Molecules and Women in Psychedelic... Read More...

Delic Announces C$7.0 Million Private Placement With Institutional Investor

/NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/ VANCOUVER, BC, Sept. 23, 2021 - Delic Holdings Corp. ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approxima... Read More...

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform VANCOUVER, BC, Sept. 23, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licen... Read More...